Cocrystal Pharma, Inc. (COCP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Cocrystal Pharma, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Cocrystal Pharma, Inc. (COCP) has returned 3.17% so far this year and -28.87% over the past 12 months. Over the last ten years, COCP has returned -42.89% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since May 19, 2011, COCP's average daily return is +0.13%, while the average monthly return is -0.75%.

Historically, 36% of months were positive and 64% were negative. The best month was Nov 2020 with a return of +158.9%, while the worst month was Apr 2018 at -64.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, COCP closed higher 35% of trading days. The best single day was Feb 13, 2012 with a return of +268.0%, while the worst single day was Jul 23, 2012 at -84.9%.

Cocrystal Pharma, Inc. has an annualized alpha of 30.94%, beta of 0.47, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since May 20, 2011.

• This stock participated in 117.05% of S&P 500 Index downside but only -86.83% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.47 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

COCP ranks 23 for risk / return — below 23% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Cocrystal Pharma, Inc. (COCP) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Cocrystal Pharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cocrystal Pharma, Inc. was 99.96%, occurring on Feb 5, 2026. The portfolio has not yet recovered.

The current Cocrystal Pharma, Inc. drawdown is 99.95%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Cocrystal Pharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Cocrystal Pharma, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.